CIK 0001980845 · <br>Emerging growth company
enGene Therapeutics Inc.
Sign in to watch- Ticker
- ENGN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Oct 31
- Incorporated
- Canada (Federal Level)
- Entity type
- operating
- Phone
- (514) 332-4888
- Business address
- 4868 RUE LEVY, SUITE 220, SAINT-LAURENT, Quebec, Canada
- Former names
- enGene Holdings Inc.
Securities
- ENGN Common Stock Nasdaq
- ENGNW Warrants Nasdaq
- 8-K Event Regulation FD disclosure
- 8-K Event Executive or director change · Other events
- 8-K Event Results of operations · Regulation FD disclosure
- 8-K Event Executive or director change · Shareholder vote results
- DEF 14A Proxy Proxy Statement
- 8-K Event Results of operations
- 8-K Event Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure
- 10-K Report Annual Report
- 8-K Event Results of operations
- 8-K Event Material agreement · New debt or obligation · Unregistered share sale
- 8-K Event Executive or director change · Regulation FD disclosure
- 8-K Event Executive or director change
- 8-K Event Executive or director change · Regulation FD disclosure
- 8-K Event Executive or director change
- 8-K Event Material agreement · Acquisition or sale completed · Unregistered share sale · Shareholder rights changed · Change in control · Executive or director change · Bylaws or fiscal year change · Code of ethics change · Shell status change
Page 3 of 3 · 55 filings